SOAT1 and Alzheimer disease: Tofacitinib is a topical small-molecular JAK inhibitor that decreases the JAK-STAT signal in keratinocytes and inhibits IL-4.85,86 Its effectiveness has been shown in plaque psoriasis and AD.87, -89 In AD, the mean EASI score was significantly improved in patients receiving tofacitinib (−81.7%) compared to those treated with vehicle (−29.9%) at week 4.89 Its oral form has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and polyarticular course juvenile idiopathic arthritis.90